Effects of L-carnitine on treatment outcomes of COVID-19 patients hospitalized in intensive care units: A double-blind randomized clinical trial

Author:

Modir Hesameddin1,Mahmoudieh Behnam1,Shahtaheri Seyed Yousef1,Farokhi Fariba2

Affiliation:

1. Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran

2. Clinical Research Development, Valiasr Hospital, Arak University of Medical Sciences, Arak, Iran

Abstract

Objective: To assess the effects of L-carnitine on the outcomes of patients with moderate to severe coronavirus disease 2019 (COVID-19) in intensive care unit (ICU). Methods: This double-blind clinical trial was carried out in 2022-2023. 64 Patients with COVID-19 were selected from Amiralmomenin and Khansari hospitals in Arak, Iran. They were randomly assigned to the control and the L-carnitine treatment group via block randomization. Venous blood gases, disease severity, and levels of D-dimer, lactate dehydrogenase, ferritin, and C-reactive protein were daily assessed during the seven days of the intervention, and the length of ICU stay, the need for endotracheal intubation, and mortality rate were documented. Results: There were significant differences in length of ICU stay, the need for endotracheal intubation, and levels of D-dimer, lactate dehydrogenase, ferritin, APACHE II score, and C-reactive protein between the two groups (P<0.05). However, the groups did not significantly differ in mortality rate and venous blood gas indexes (P>0.05). Conclusions: L-carnitine can improve outcomes of patients with COVID-19. Therefore, it can be used as an adjuvant therapy for these patients. Trial registration: Iranian Registry of Clinical Trials identifier IRCT20141209020258N165.

Publisher

Medknow

Reference34 articles.

1. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - An update on the status;Guo;Mil Med Res,2020

2. Maternal death due to severe and critical COVID-19 in Qom, Iran: A case series;Yousefzadeh;J Acute Dis,2022

3. Respiratory infections in the aging lung: Implications for diagnosis, therapy, and prevention;Häder;Aging Dis,2023

4. COVID-19 and management of severe acute respiratory infection (SARI): A questionnaire-based study among indian healthcare professionals;Patankar;Curr Health Sci J,2020

5. COVID-19 (Coronavirus disease 2019): A new coronavirus disease;Sadeghi;Infect Drug Resist,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3